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ABSTRACT
Introduction There is growing evidence of a higher than 
expected prevalence of retinopathy in prediabetes. This 
paper presents the protocol of a systematic review and 
meta- analysis of retinopathy in prediabetes. The aim of 
the review is to estimate the prevalence of retinopathy in 
prediabetes and to summarise the current data.
Methods and analysis This protocol is developed 
in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta- Analyses Protocols 
(PRISMA- P) guidelines. A comprehensive electronic 
bibliographic search will be conducted in MEDLINE, 
EMBASE, Web of Science, Cumulative Index to Nursing and 
Allied Health Literature (CINAHL), Google Scholar and the 
Cochrane Library. Eligible studies will report prevalence 
data for retinopathy on fundus photography in adults 
with prediabetes. No time restrictions will be placed on 
the date of publication. Screening for eligible studies 
and data extraction will be conducted by two reviewers 
independently, using predefined inclusion criteria and 
prepiloted data extraction forms. Disagreements between 
the reviewers will be resolved by discussion, and if 
required, a third (senior) reviewer will arbitrate.
The primary outcome is the prevalence of any standard 
features of diabetic retinopathy (DR) on fundus 
photography, as per International Clinical Diabetic 
Retinopathy Severity Scale (ICDRSS) classification. 
Secondary outcomes are the prevalence of (1) any retinal 
microvascular abnormalities on fundus photography 
that are not standard features of DR as per ICDRSS 
classification and (2) any macular microvascular 
abnormalities on fundus photography, including but 
not limited to the presence of macular exudates, 
microaneurysms and haemorrhages. Risk of bias for 
included studies will be assessed using a validated risk of 
bias tool for prevalence studies. Pooled estimates for the 
prespecified outcomes of interest will be calculated using 
random effects meta- analytic techniques. Heterogeneity 
will be assessed using the I2 statistic.
Ethics and dissemination Ethical approval is not 
required as this is a protocol for a systematic review 
and no primary data are to be collected. Findings will be 
disseminated through peer- reviewed publications and 
presentations at national and international meetings 
including Diabetes UK, European Association for the 
Study of Diabetes, American Diabetes Association and 
International Diabetes Federation conferences.
PROSPERO registration number CRD42020184820.
BACKGROUND
Prediabetes is defined by blood glucose 
levels above the normal range but below 
the threshold for type 2 diabetes mellitus.1 2 
The burden of prediabetes is enormous: it is 
currently estimated to affect 373 million people 
across the globe and this number is projected 
to increase to 587 million (8.3% of the global 
adult population) by 2045.3
Cohort analyses of people with prediabetes 
reveals an increased incidence of microvas-
cular and macrovascular disease, including 
an elevated all- cause mortality, compared to 
people with normal glucose metabolism.4 5 
This suggests that end- organ complications of 
hyperglycaemia may be occurring prior to the 
onset of overt diabetes.6 Furthermore, people 
with prediabetes and microvascular disease 
are more likely to develop overt diabetes.7 8 In 
a population- based analysis of 49 072 people 
with diabetes, the presence of diabetic 
retinopathy (DR) was associated with an 
increased risk (HR 1.39, 95% CI 1.09 to 1.76) 
of cardiovascular death, non- fatal myocar-
dial infarction or stroke, after adjustment of 
traditional risk factors including HbA1c, lipid 
profile and blood pressure.9 Despite ongoing 
debate on how best to identify people with 
prediabetes at high risk of end- organ compli-
cations, long- term data show a reduction in 
both morbidity and mortality following early 
lifestyle interventions.10
Strengths and limitations of this study
 ► This systematic review protocol follows the Preferred 
Reporting Items for Systematic Review and Meta- 
Analyses Protocols (PRISMA- P) guidelines.
 ► This systematic review addresses an important gap 
in the current evidence by estimating the prevalence 
of retinopathy in prediabetes.
 ► There is potential for significant clinical and statisti-
cal heterogeneity in the reporting of prevalence data 
between different populations.
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A systematic review of 35 population- based studies of 
people with diabetes reported the prevalence of DR, 
proliferative DR, diabetic macular oedema and vision- 
threatening DR as 34.6%, 7.0%, 6.8% and 10.2%, respec-
tively.11 The early onset of retinopathy in prediabetes is 
of particular concern as DR remains one of the principal 
causes of vision loss in adults of working age in developed 
countries, with considerable health and socioeconomic 
consequences.12 Given projections that up to 70% of 
people with prediabetes may eventually develop diabetes 
during their lifespan, early identification of retinopathy 
is a significant health priority.6 It is estimated that up to 
95% of vision loss in diabetes is preventable or treatable, 
if detected early.13
Previous studies have suggested that isolated retinop-
athy changes occur in 5%–10% of the general population 
and in 2.6%–8.6% of those without diabetes or hyperten-
sion.14 15 Although several studies have reported retinop-
athy changes in prediabetes, there has been no systematic 
review or meta- analysis of the literature to estimate an 
overall prevalence. Establishing the prevalence of retinop-
athy may not only focus attention on early interventions 
but also help refine diagnostic criteria and risk stratifi-
cation for prediabetes. The aim of this systematic review 
is to estimate the prevalence of retinopathy detected on 
fundus photography in adults with prediabetes.
METHODS AND ANALYSIS
Study design
Comprehensive literature searches of electronic 
bibliographic databases will be conducted in MEDLINE 
(access via OVID), EMBASE (access via OVID), Web 
of Science, CINAHL (Cumulative Index to Nursing 
and Allied Health Literature), Google Scholar and the 
Cochrane Library. No time restrictions will be placed on 
the date of publication. All search strategies will be inde-
pendently reviewed by an expert information specialist 
using the Peer Review of Electronic Search Strategies 
checklist, and a draft MEDLINE search strategy is included 
in online supplemental appendix 1.16 Additional articles 
will be identified by searching the references of included 
studies and other review articles identified during the 
course of the searches. Results from the database searches 
will be merged using an electronic reference manager 
to facilitate removal of duplicates. Trial registries such 
as  ClinicalTrials. gov will be consulted to identify studies 
that may not have been indexed in the databases. Rele-
vant publications will be retrieved manually if electronic 
access is not available.
Participants, eligibility and setting
Inclusion criteria will be adults over 18 years of age who 
have prediabetes defined by American Diabetes Associ-
ation (ADA) criteria.1 This includes impaired fasting 
glucose (IFG) and impaired glucose tolerance (IGT) as 
subgroups of prediabetes. Population- based cohort or 
cross- sectional studies from any country in any setting 
will be considered, provided they have been reported in 
English. Studies must report prevalence data for retinop-
athy detected on fundus photography, using any accepted 
method (eg, 1- field, 2- field, 3- field or 7- field dilated 
stereoscopic colour fundus photography) at least once in 
the study population. A lack of detail on the method used 
or quality of images taken will be documented but will not 
be considered an exclusion criterion. Studies that report 
other methods of imaging, such as fluorescein angiog-
raphy or optical coherence tomography, will be included 
only if fundus photography data are also provided. Use 
of alternative diagnostic criteria for prediabetes, such 
as World Health Organization (WHO) criteria, will be 
recorded and prevalence figures reported separately but 
will not be considered a reason for exclusion.2 A lack of 
reporting of the definition of prediabetes and/or reti-
nopathy will be documented but will not be considered a 
reason for exclusion.
Outcomes
The primary outcome is the prevalence of any standard 
features of DR on fundus photography, as per Inter-
national Clinical Diabetic Retinopathy Severity Scale 
(ICDRSS) classification.17 This will be defined by the pres-
ence of any of the following features:
 ► Microaneurysms.
 ► Intraretinal haemorrhages.
 ► Hard exudates.
 ► Cotton- wool spots.
 ► Venous beading.
 ► Intraretinal microvascular abnormalities (IRMA).
 ► New vessels at the optic disc (NVD) or elsewhere 
(NVE).
 ► Vitreous or preretinal haemorrhage.
Secondary outcomes are the prevalence of: (1) 
any retinal microvascular abnormalities on fundus 
photography that are not standard features of DR as per 
ICDRSS classification and (2) any macular microvascular 
abnormalities on fundus photography, including but not 
limited to the presence of macular exudates, microaneu-
rysms or haemorrhages.
If available, data on glycaemic parameters such as 
fasting glucose, 2- hour oral glucose tolerance test and 
HbA1c will be extracted. Similarly, if reported, preva-
lence data on cardiovascular parameters such as systolic 
and diastolic blood pressure, lipid profile and metabolic 
syndrome will also be extracted. Metabolic syndrome 
will be defined as per consensus criteria based on WHO, 
National Cholesterol Education Program Adult Treat-
ment Panel III and ADA classifications.2 18–21
Study selection
Two reviewers will independently screen titles and 
abstracts from the searches and exclude any that clearly 
do not satisfy the inclusion criteria. Any disagreements 
will be resolved by discussion, and if required, a third 
(senior) reviewer will arbitrate. Articles of interest will be 
selected for a full- text assessment. If there is any doubt 
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regarding the eligibility of a study, the article will be 
selected for full- text assessment.
Two reviewers will independently assess the full- text 
articles against the eligibility criteria. Disagreements 
between these reviewers will be resolved by discussion, 
and if required, a third (senior) reviewer will arbitrate.
A Preferred Reporting Items for Systematic Reviews 
and Meta- Analyses (PRISMA) flowchart of the selection 
process will be included in the systematic review.22
Data collection process
Two reviewers will independently extract data in dupli-
cate using pre- piloted forms. Data recorded will include: 
(1) date and country of study; (2) study design; (3) age, 
gender and ethnicity of participants; (4) definition of 
retinopathy and method(s) used to obtain images; (5) 
definition of prediabetes and method(s) used to make 
diagnosis; (6) study groups and sizes; (7) overall sample 
size and (8) prevalence number and estimate. If present, 
secondary outcome data will also be recorded, including 
(1) definition and prevalence of non- standard reti-
nopathy features and (2) definition and prevalence of 
maculopathy features. Where reported, prevalence esti-
mates for comorbid ocular pathology (eg, cataract) and 
cardiovascular risk factors (eg, hypertension, metabolic 
syndrome) will also be recorded.
Risk of bias assessment
A modified critical appraisal tool for specifically assessing 
risk of bias in prevalence studies will be used on selected 
articles and is included in online supplemental appendix 
2.23 The tool includes 9 questions, each scoring 0 or 1, to 
determine confounding, selection bias and bias related 
to measurement and data analysis. Overall risk of bias 
will be determined by the total score for each article: 0–3 
considered low risk, 4–6 considered moderate risk and ≥7 
considered high risk. Quality assessment will be under-
taken by two reviewers independently. Disagreements will 
be resolved by discussion, and if required, a third (senior) 
reviewer will arbitrate. Judgements on the overall risk of 
bias will be categorised as either low, moderate or high 
risk, based on the risk of bias of the 10 individual items 
listed within the tool.
Data analysis
Data will be analysed using purpose- built software for 
systematic reviews and meta- analyses (Review Manager 
V.5). Heterogeneity between included studies will be 
assessed based on study design, populations and methods 
used to measure outcomes. Statistical heterogeneity will 
be assessed using the I2 statistic and by visual inspection 
of forest plots.
Characteristics of included studies will be presented in 
summary tables and narrative text. In expectation of prev-
alence varying between studies and populations, pooled 
prevalence estimates for the prespecified outcomes of 
interest will be calculated applying random effects meta- 
analytic methods and reported in forest plots.
Where clinical and/or statistical heterogeneity is 
deemed too large by the reviewers (eg, I2 ≥90%), a system-
atic review without meta- analysis will be reported. Narra-
tive synthesis will be conducted where quantitative data 
required for meta- analysis is lacking or absent.
Depending on availability of data, subgroup analyses 
using the following covariates will also be considered:
 ► WHO region or country.
 ► Age group (eg, 18–30, 31–50, >50 years).
 ► Ethnicity (especially at- risk groups, eg, South Asian, 
African, Afro- Caribbean, Hispanic).
 ► Time since diagnosis of prediabetes (eg, <1 year, 1–5 
years, 6–10 years, >10 years).
 ► Subtype of prediabetes (eg, IFG compared with IGT).
 ► Grade of retinopathy as per ICDRSS classification.
 ► Comorbid ocular pathology (eg, cataract).
 ► Comorbid cardiovascular risk factors (eg, hyperten-
sion, metabolic syndrome).
 ► Method or criteria used to diagnose prediabetes (eg, 
WHO).
 ► Method used to diagnose retinopathy (eg, 7- field 
stereoscopic imaging).
If sufficient data are available, a sensitivity analysis will 
be performed excluding studies judged to be at high risk 
of bias.
Grading of evidence
Certainty of the evidence will be assessed using the 
Grading of Recommendations, Assessment, Development 
and Evaluations (GRADE) approach.24 25 Specifically, 
prevalence studies will be considered to constitute high- 
certainty evidence to answer this review question and 
downgraded for risk of bias, imprecision, inconsistency, 
indirectness and publication bias. Two reviewers will inde-
pendently make this judgement. Disagreements will be 
resolved by discussion, and if required, a third (senior) 
reviewer will arbitrate.
Patient and public involvement
There were no time or funds allocated to patient and 
public involvement, particularly in the context of the 
current COVID-19 pandemic, so the reviewers were 
unable to involve patients. However, this systematic review 
asks an important clinical question and the protocol 
described follows a standardised approach as per PRIS-
MA- P guidelines. People with prediabetes will be invited 
to help the reviewers develop a strategy to disseminate 
the results.
ETHICS AND DISSEMINATION
This study is a systematic review using aggregated 
published data, without accessing any personal identifi-
able information, hence there are no significant ethical or 
safety concerns. The results of this study will be presented 
at international conferences and submitted for publica-
tion in a peer- reviewed open- access journal. Authors will 
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use their networks to encourage broad dissemination of 
the results.
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